

FoI request re: Adalimumab therapy

Ref: 20-JM-1003

Thank you for your request for information relating to Adalimumab therapy.

This was received on 11 February 2020 and has been dealt with under the terms of the Freedom of Information Act 2000.

Please find our responses below:

Request 1:

	Rheumatology	Dermatology	Gastroenterology
Is the branded biosimilar AMGEVITA listed on your formulary?	Yes	Yes	Yes

Request 2:

Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

Product/place in the adalimumab therapy pathway*	Rheumatology	Dermatology	Gastroenterology
AMGEVITA first-line	≤5	≤5	≤5
AMGEVITA second-line	55	≤5	10
HUMIRA first-line	0	0	0
HUMIRA second-line	0	0	0
HYRIMOZ first-line	≤5	≤5	≤5
IMRALDI first-line	0	0	0

**How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.*

Please note that the trust's policy is not to provide patient or staff numbers, where the response is less than or equal to five (≤5) as it would potentially allow identification of the individual patient/staff and would therefore be personal data. The trust considers that release of that information would breach GDPR/DPA18 principles on the grounds that it would not be fair in all the circumstances. This information is therefore exempt under section 40 of the FOI Act 2000.

Request 3:

Please complete the table below:

Department

Whittington Health NHS Trust

Interim Chair: Anu Singh Chief Executive: Siobhan Harrington

Question	Dermatology	Rheumatology			Gastroenterology	
	Psoriasis	Psoriatic arthritis	Rheumatoid arthritis	Ankylosing spondylitis	Crohn's disease	Ulcerative colitis
Are any local guidelines followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway?	No	No	No	No	No	No
Are there occasions where patients can receive adalimumab outside of NICE/SMC/AWMSG/ National criteria?	No	No	No	No	No	No

Request 4:

What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards? [Payment by Results \(PbR\)](#)

Contractual agreement	Yes/No
Block contracts	
Fixed price on a patient-by-patient basis	

I hope you find this information useful. Please quote the above reference in any further communication on this matter.

If you require any further assistance, please do not hesitate to contact me by email or at the address shown below.

Yours sincerely

FOI Coordinator
Freedom of Information Office
 Whittington Health
 Highgate Wing, Level 5
 Magdala Avenue
 London, N19 5NF
foi.whitthealth@nhs.net

Whittington Health NHS Trust

Interim Chair: Anu Singh Chief Executive: Siobhan Harrington

If you are dissatisfied with this response, Whittington Health operates a complaints procedure, details of which can be found below:

FOI Complaints:

In the first instance, write to:

Director Lead for Information

Governance

Chief Operating Officer

Jenner Building

Magdala Avenue

London

N19 5NF

020 7288 5255

foi.whitthealth@nhs.net

If you remain dissatisfied with the Trust's response, you may write to:

Information Commissioner's Office

Wycliffe House

Water Lane

Wilmslow

Cheshire SK9 5AF

Telephone: 0303 123 1113 or 01625 545745

www.ico.org.uk

Whittington Health NHS Trust

Interim Chair: Anu Singh

Chief Executive: Siobhan Harrington